Opus Genetics Aligns With FDA In A Type B Rare Disease Meeting On Design Of Its Registrational Phase 3 Clinical Trial Evaluating OPGX-lCA5 F
Opus Genetics has received the meeting minutes from the Type B meeting confirming several key elements of the trial. The Phase 3 study is expected to enroll eight participants who are able to complete microperimetry testing with both eyes treated. The study is also expected to include a six-month run-in period, allowin